Physician profile
Viral Doshi
NPI 1164654117
$55,684.96
in general payments reported to CMS, 2019-2025
53 companies · $5,395 in 2025
The $5,395 reported for 2025 was more than what 94% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $4,776 · 2021: $2,309 · 2022: $1,748 · 2023: $3,966 · 2024: $19K · 2025: $5,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $6,696 · Consulting Fee: $4,589 · Travel and Lodging: $2,149 · Education: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,794.00 |
| Food and Beverage | $6,695.63 |
| Consulting Fee | $4,589.00 |
| Travel and Lodging | $2,149.17 |
| Education | $309.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $20,286.55 | 2019-2025 | |
| Mylan Specialty L.P. | $18,470.36 | 2019-2024 | Yupelri |
| Inspire Medical Systems, INC. | $3,001.52 | 2020-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $2,646.92 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Harmony Biosciences LLC | $2,042.57 | 2020-2025 | Wakix |
| Glaxosmithkline, LLC. | $1,832.63 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,156.80 | 2019-2025 | Ofev, Jascayd |
| Genzyme Corporation | $898.49 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $522.10 | 2019-2024 | Dupixent |
| Avadel Cns Pharmaceuticals, LLC | $453.37 | 2023-2025 | Lumryz |
| Axsome Therapeutics, INC. | $380.60 | 2023-2025 | Sunosi |
| Merck Sharp & Dohme LLC | $300.73 | 2019-2025 | Winrevair |
| Sunovion Pharmaceuticals INC. | $297.43 | 2019-2020 | |
| Genentech USA, INC. | $278.58 | 2019-2022 | |
| Amgen INC. | $236.74 | 2022-2025 | Tezspire |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viral Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.